We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva to Discontinue a Fremanezumab Study on Cluster Headache
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that it will discontinue the phase III study evaluating its key pipeline candidate, fremanezumab for the treatment of chronic cluster headache. This decision was based on data from a pre-specified futility analysis of the study, which showed that the study is unlikely to meet its primary endpoint of mean change from baseline in the monthly average number of cluster headache attacks over a 12-week period.
The ENFORCE Phase III clinical development program comprised the chronic cluster headache study, an episodic cluster headache analysis and a long-term safety study.
Notably, evaluation of the patients with chronic cluster headache in the long-term safety study will also be stopped. However, the study on episodic cluster headache will not be affected and carried out as planned.
Fremanezumab, an anti-calcitonin gene-related peptide (“CGRP”) candidate, is currently under review in the United States and Europe for the preventive treatment of migraine in adults as a quarterly or monthly injection. However in May, the company announced that the FDA has postponed the action date from June to September.
Shares of the company slipped 0.8% including after-hours trading on Jun 15. However, the stock has rallied 25.4% so far this year compared with the industry’s increase of 2.2%.
Teva is focused on developing fremanezumab beyond migraine for indications like cluster headache and post traumatic headache disorder.
We saw Alder Biopharmaceuticals Inc’s share price rise 6.7% on Friday following the news of Teva’s decision to suspend the cluster headache study. We note that Alder is also developing an anti-CGRP candidate, eptinezumab, for the preventive treatment of migraine. The candidate is being evaluated in pivotal study with a Biologics License Application expected to be filed with the FDA during the first quarter of 2019.
Meanwhile, several other companies are developing treatments for treating migraine, a multi-billion dollar segment with high unmet need. In May, the FDA approved Amgen (AMGN - Free Report) and its partner Novartis’ (NVS - Free Report) anti-CGRP drug, Aimovig, for treating episodic migraine. Other anti-CGRP candidates under development include Eli Lilly’s galcanezumab and Allergan’s atogepant.Galcanezumab is under review in the United States for preventive treatment of migraine. Lilly is also developing the candidate for cluster headache.
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Teva to Discontinue a Fremanezumab Study on Cluster Headache
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that it will discontinue the phase III study evaluating its key pipeline candidate, fremanezumab for the treatment of chronic cluster headache. This decision was based on data from a pre-specified futility analysis of the study, which showed that the study is unlikely to meet its primary endpoint of mean change from baseline in the monthly average number of cluster headache attacks over a 12-week period.
The ENFORCE Phase III clinical development program comprised the chronic cluster headache study, an episodic cluster headache analysis and a long-term safety study.
Notably, evaluation of the patients with chronic cluster headache in the long-term safety study will also be stopped. However, the study on episodic cluster headache will not be affected and carried out as planned.
Fremanezumab, an anti-calcitonin gene-related peptide (“CGRP”) candidate, is currently under review in the United States and Europe for the preventive treatment of migraine in adults as a quarterly or monthly injection. However in May, the company announced that the FDA has postponed the action date from June to September.
Shares of the company slipped 0.8% including after-hours trading on Jun 15. However, the stock has rallied 25.4% so far this year compared with the industry’s increase of 2.2%.
Teva is focused on developing fremanezumab beyond migraine for indications like cluster headache and post traumatic headache disorder.
We saw Alder Biopharmaceuticals Inc’s share price rise 6.7% on Friday following the news of Teva’s decision to suspend the cluster headache study. We note that Alder is also developing an anti-CGRP candidate, eptinezumab, for the preventive treatment of migraine. The candidate is being evaluated in pivotal study with a Biologics License Application expected to be filed with the FDA during the first quarter of 2019.
Meanwhile, several other companies are developing treatments for treating migraine, a multi-billion dollar segment with high unmet need. In May, the FDA approved Amgen (AMGN - Free Report) and its partner Novartis’ (NVS - Free Report) anti-CGRP drug, Aimovig, for treating episodic migraine. Other anti-CGRP candidates under development include Eli Lilly’s galcanezumab and Allergan’s atogepant.Galcanezumab is under review in the United States for preventive treatment of migraine. Lilly is also developing the candidate for cluster headache.
Teva Pharmaceutical Industries Ltd. Price
Teva Pharmaceutical Industries Ltd. Price | Teva Pharmaceutical Industries Ltd. Quote
Teva currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>